OIT3 Biomarker qRT-PCR Detection for Early HCC Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for hepatocellular carcinoma (HCC) lack sensitivity and specificity, particularly in early stages, and existing tumor markers like AFP have limitations in detecting smaller lesions and predicting clinical prognosis.
Innovation Solution
A novel tumor marker, OIT3, is identified and used in conjunction with qRT-PCR to detect its expression levels in peripheral blood and HCC tissues, providing a diagnostic reagent and prediction model for improved early detection and prognosis assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum AFP detection is used for HCC diagnosis, then the accuracy of diagnosis is improved, but the sensitivity for early-stage and small lesions remains insufficient
Solution Approach 1:
The patent changes the detection parameter from AFP protein levels to OIT3 gene expression levels. By detecting mRNA expression through qRT-PCR, the method identifies early-stage HCC with higher sensitivity while maintaining diagnostic accuracy, directly resolving the contradiction between detection sensitivity and diagnostic accuracy
Solution Approach 2:
The patent introduces OIT3 as an intermediary biomarker that bridges the gap between traditional AFP detection and early tumor detection. OIT3 serves as a more sensitive mediator that can detect molecular changes before they manifest as detectable protein levels or imaging abnormalities, thereby improving both sensitivity and accuracy
2Measurement precision
If imaging modalities are used for detecting HCC lesions smaller than 2 cm, then the detection capability is improved, but the sensitivity remains poor due to incomplete tumor vascular structure
Solution Approach 1:
The patent replaces mechanical imaging modalities (which rely on physical structures like blood vessels) with molecular biology detection methods. By detecting OIT3 gene expression in serum or tissue, the method bypasses the limitation of incomplete tumor vascular structure and achieves high sensitivity for small lesions without relying on mechanical imaging principles
3Ease of operation
If traditional tumor markers are used for early HCC detection, then the diagnostic workflow is maintained, but the detection sensitivity for early-stage lesions is insufficient
Solution Approach 1:
The patent changes the detection parameter from traditional AFP protein levels to OIT3 gene expression levels while maintaining the familiar serum or tissue sample collection workflow. The qRT-PCR detection method integrates smoothly into existing diagnostic workflows, preserving ease of operation while dramatically improving early lesion detection sensitivity through molecular-level detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
OIT3 enhances the accuracy and simplicity of HCC diagnosis, offering a practical and convenient tool for wider application and improved clinical outcomes by inhibiting proliferation, invasion, and metastasis of hepatoma cells.
Implementation Method 1
the level of expression of the OIT3 in peripheral blood and HCC tissues of patients with HCC is detected using qRT-PCR
Data Source
AI summary
The present disclosure relates to a newly discovered tumor marker for hepatocellular carcinoma (HCC) and related applications thereof in clinical detection. The tumor marker for HCC in the present disclosure is OIT3, which is abnormally expressed at low levels in HCC tissues and can be used in the diagnosis and treatment of HCC. The present application further relates to primer sequences of OIT3 as an HCC marker, which can be used as a reagent for the detection and diagnosis of HCC. The present disclosure can improve the accuracy, efficiency, and diagnosis of early HCC and is suitable for popularization in the clinical diagnosis of HCC.